Clinical Trial Update: A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for EHT102 injection (Phase 1/2) in pediatric patients with congenital hearing loss due to biallelic OTOF mutations; the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hearing Loss

Drugs mentioned

• EHT102

Snippet

Sponsor: Shanghai Euhearing Therapeutics Co., Ltd | Conditions: Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1, Phase 2 | Status: RECRUITING